Jongmyung Kim, MD, PhD

My research focuses on developing innovative theranostic strategies—including peptide-directed immuno-radiotherapy, radiopharmaceuticals, bispecific antibodies, and radiation-guided immune modulation—to overcome therapeutic resistance in primary and metastatic lung cancers. By integrating precision genomics and clinical trial design, I aim to advance personalized therapies that improve outcomes for patients with advanced or treatment-refractory disease.

Associations

• Radiation Oncology
• Immunology
• Immuno-Oncology Program

Education & Training

Board Certification:

• Radiation Oncology -

Fellowship:

• Moffitt Cancer Center (Tampa, FL) - Department of Neuro-Oncology (Cancer Stem Cell Biology)
• Cleveland Clinic (Cleveland, OH) - Department of Stem Cell Biology (Cancer Stem Cell Biology)
• Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) - Section of Urologic Oncology (Cancer Cell Biology)

Residency:

• Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) - Radiation Oncology (Residency)
• University of Louisville School of Medicine (Louisville, KY) - General Surgery (Internship)

Medical School:

• Pusan National University School of Medicine (South Korea) - MD/PhD

My research focuses on developing and translating novel theranostic strategies to overcome therapeutic resistance in primary and metastatic lung cancer. I employ phage display technologies to identify and engineer tumor-specific peptides for peptide-directed immuno-radiotherapy, radiopharmaceuticals, and bispecific antibody platforms designed to enhance tumor targeting and immune modulation. In parallel, my work investigates radiation-guided immune modulation as a synergistic approach to amplify anti-tumor immunity and sensitize resistant cancers to therapy. By integrating genomics-driven precision oncology, I aim to define molecular drivers of resistance and tumor heterogeneity, and translate these insights into clinical trial designs that accelerate the delivery of personalized cancer care. Central to my efforts is the advancement of innovative combinations of radiotherapy, immunotherapy, and novel biologics through multidisciplinary collaborations, with the ultimate goal of improving outcomes for patients with advanced or treatment-refractory lung cancers.

• Deek RA, Kim J, Kumar R, Medina B, Langenfeld J, Kontopidis I, Lazzaro R, Nie K, Hathout L, Guler O, Onal C, Patel E, Haigentz M, Jabbour SK, Deek MP. Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2025 Nov.26(7):e609-e615.e11. Pubmedid: 40897601.
• Cruz-Chamorro R, Bryant JM, Henning J, Robinson LA, Lee DH, Fontaine J, Toloza E, Rosenberg SA, Kim J, Naqa IE, Dilling TJ. Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients. Radiother Oncol. 2025 Nov.212:111117. Pubmedid: 40854381.
• Chafe SC, Zhai K, Aghaei N, Miletic P, Huang Z, Brown KR, Mobilio D, Young D, Suk Y, Grewal S, McKenna D, Alizada Z, Kieliszek AM, Lam FC, Escudero L, Huang Q, Huebner A, Lu J, Ang P, Anand A, Custers S, Apel E, Slassi S, Brakel B, Kim J, Liu JKC, Bassey-Archibong BI, Abdo R, Shargall Y, Lu JQ, Cutz JC, Zhang Q, Li SS, Venugopal C, Hynds RE, Dufour A, Moffat J, Swanton C, Bao S, Singh SK. A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis. Sci Transl Med. 2025 Jul.17(805):eadu2459. Pubmedid: 40601773. Pmcid: PMC7617989.
• Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Tran PT, Deek MP. PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. Prostate. 2024 Oct.84(14):1301-1308. Pubmedid: 39021052.
• Wang T, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Deek MP. Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer. Transl Cancer Res. 2024 Nov.13(11):6235-6245. Pubmedid: 39697761. Pmcid: PMC11651787.
• Kim J, Fahmy V, Haffty BG. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Rev Anticancer Ther. 2024 May.24(5):211-217. Pubmedid: 38502143.
• Huang Q, Liu L, Xiao D, Huang Z, Wang W, Zhai K, Fang X, Kim J, Liu J, Liang W, He J, Bao S. CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. Cancer Cell. 2023 Sep.41(9):1621-1636.e8. Pubmedid: 37595587.
• Kim J, Haffty BG. Genetic Factors in the Screening and Imaging for Breast Cancer. Korean J Radiol. 2023 May.24(5):378-383. Pubmedid: 37056158. Pmcid: PMC10157325.
• Potez M, Snedal S, She C, Kim J, Thorner K, Tran TH, Ramello MC, Abate-Daga D, Liu JKC. Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells. Front Oncol. 2023 Mar.13:1124272. Pubmedid: 37035164. Pmcid: PMC10080078.
• Kim J, Mukherji S, Haigentz M, Stubbs VC, Kim S. A rare pattern of local recurrence in the nasopharyngeal carcinoma: Case report. Otolaryngol Case Rep. 2023 Jun.27.
• Kumar R, Kim J, Deek MP, Eskander MF, Gulhati P, In H, Kennedy T, Shah MM, Grandhi MS, Berim L, Spencer KR, Langan RC, Hochster HS, Boland PM, Jabbour SK. Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research. Curr Oncol. 2023 Jul.30(7):6432-6446. Pubmedid: 37504333. Pmcid: PMC10378032.
• Kim J, Potez M, She C, Huang P, Wu Q, Bao S, Rich JN, Liu JKC. Glioblastoma Stem Cell Targeting Peptide Isolated Through Phage Display Binds Cadherin 2. Stem Cells. 2023 Aug.41(8):762-774. Pubmedid: 37280108. Pmcid: PMC10427963.
• Kim J, She C, Potez M, Huang P, Wu Q, Prager BC, Qiu Z, Bao S, Rich JN, Liu JKC. Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation. Stem Cells. 2021 Jul.39(7):853-865. Pubmedid: 33594762. Pmcid: PMC10741052.
• Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, Jamieson C, Kim WJ, Kim IY. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Brit J Cancer. 2018 Mar.118(5):670-678. Pubmedid: 29381686. Pmcid: PMC5846063.
• Yu J, Kwon YS, Kim S, Han CS, Farber N, Kim J, Byun SS, Kim WJ, Jeon SS, Kim IY. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. J Urol. 2016 May.195(5):1464-1470. Pubmedid: 26608903. Pmcid: PMC5769700.
• Kim JM, Cho HH, Lee SY, Hong CP, Yang Jw, Kim YS, Suh KT, Jung JS. Role of IRAK1 on TNF-induced proliferation and NF-ĸB activation in human bone marrow mesenchymal stem cells. Cell Physiol Biochem. 2012 Oct.30(1):49-60. Pubmedid: 22759955.
• Kim JM, Yu JM, Bae YC, Jung JS. Analysis of Global Gene Expression Profile of Human Adipose Tissue Derived Mesenchymal Stem Cell Cultured with Cancer Cells. Saengmyeong gwahag hoeji. 2011 May.21(5):631-646.
• Kim JM, Song JS, Cho HH, Shin KK, Bae YC, Lee BJ, Jung JS. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor. Mol Cell Biochem. 2011 Jan.346(1-2):125-136. Pubmedid: 20890637.
• Cho HH, Shin KK, Kim YJ, Song JS, Kim JM, Bae YC, Kim CD, Jung JS. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol. 2010 Apr.223(1):168-177. Pubmedid: 20049872.